Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform combines the company’s PDAOAI technology with advanced robotics provided through its collaboration with TechForce Robotics to support pharmaceutical, biotechnology and advanced therapeutics companies seeking to modernize manufacturing operations through AI-driven workflows, digital quality systems and intelligent automation.
According to Oncotelic, the platform is designed to support electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions and process monitoring. The company also plans to showcase progress with its Deciparticle nanomedicine platform, including SAPU003, its clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study. For more details, the full press release is available at https://ibn.fm/upnBW.
This launch comes amid growing industry demand for advanced manufacturing solutions that can improve efficiency, reduce errors, and ensure regulatory compliance. By integrating AI and robotics, Oncotelic aims to offer a streamlined approach to GMP manufacturing, potentially lowering costs and accelerating time-to-market for drug developers. The platform’s ability to digitize batch records and workflows could also help companies meet stringent quality standards more consistently.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company’s pipeline includes both internally developed and licensed drug candidates. Notably, Oncotelic owns 45% of GMP Bio, a joint venture under the leadership of its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents.
The PDAOAI platform, central to the new offering, is Oncotelic’s proprietary AI system for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through Oncotelic’s relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins the Platform and its ongoing joint development work with TechForce Robotics, Oncotelic’s strategic robotics and automation partner. TechForce Robotics, the operating brand of Nightfood Holdings, Inc., designs and deploys purpose-built robotics and automation solutions for service, hospitality, and pharmaceutical manufacturing applications. More information is available at https://www.techforcerobotics.com.
The announcement at BIO 2026 signals Oncotelic’s commitment to leveraging cutting-edge technology to address challenges in pharmaceutical manufacturing. For the industry, this platform could provide a scalable solution for smaller biotech firms that lack in-house GMP capabilities, potentially democratizing access to high-quality manufacturing services. The integration of AI also positions the platform to adapt to evolving regulatory requirements and improve operational transparency.
Investors and stakeholders can find the latest news and updates on OTLC at the company’s newsroom: https://ibn.fm/OTLC.
